Pulmonary carcinoma is a main cause of cancer death internationally. Chemotherapeutic regimens in most solid tumors have limited effect. And in the targeted inhibition of carcinogenic driver mutations with molecular therapies, in a large number of cases, patients acquire resistance to drugs. Therefore, the development of new therapeutic approaches is highly desirable. In the present study, we evaluated the applicability of 4 [(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid (Am80), a synthetic retinoid, as a differentiation inducer in pulmonary carcinoma and examined its effect on the viability and differentiation of Calu-6 cells (a human nonsmall cell lung cancer cell line), with the final goal of establishing a new approach to pulmonary carcinoma therapy.
Introduction
Pulmonary carcinoma is a main cause of cancer death internationally [1] . In particular, non-small cell lung cancer (NSCLC) accounts for about 85% of all pulmonary carcinoma cases. Pulmonary carcinomas are categorized into three histological subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma [2] . As the prognosis of pulmonary carcinoma is poor, the development of new therapeutic approaches is highly desirable [3] . Pulmonary adenocarcinoma, which accounts for about 40% of all pulmonary carcinomas, is currently the main histological type and its incidence has increased gradually [4] .
Chemotherapeutic regimens in most solid tumors have limited effect and are associated with significant toxic effect. In the last decade, the targeted inhibition of carcinogenic driver mutations with molecular therapies, such as epidermal growth factor receptor and the anaplastic lymphoma kinase, has brought spectacular improvements in the overall survival in defined subsets of patients [5] . Unfortunately, in a large number of cases, patients acquire resistance to these drugs due to secondary mutations and other mechanisms [6] .
We became aware of a retinoic acid inductor as a cell-growth inhibitor and differentiation inducer in pulmonary adenocarcinoma. Retinoids reduce the growth and induce the differentiation of a variety of types of tumor cells in vitro and in vivo [7] . A novel synthetic retinoid, 4 [(5,6,7,8-tetrahydro-5,5,8,8 -tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid (Am80), has been developed and utilized for the treatment of acute promyelocytic leukemia. Am80 offers a higher differentiation-inducing characteristic and is about ten times more powerful than All-trans retinoic acid (ATRA) as an in vitro differentiation-inducer in the NB-4 acute myelocytic leukemia and HL-60 human leukemia cell lines [8, 9] . Furthermore, Am80 is chemically more stable to light, heat, and oxidation and has higher receptor selectivity than ATRA. Am80 is a synthetic selective agonist for nuclear retinoic acid receptor (RAR)-α, and RAR-β, and does not bind to RAR-γ, which is the main RAR in the dermal epithelium [10] . In regard to metabolic characteristics, Am80 is also stable in the presence of retinoic acid-metabolizing enzyme CYP26A1 and faintly binds to cellular retinoic acid-binding protein (CRABP), which may lead to ATRA resistance [11] [12] [13] . The affinity of Am80 against CRABP is approximately one-twentieth that of ATRA. Although Am80 has defined advantages over ATRA, its differentiation-inducing effect on pulmonary carcinoma has not been investigated. We previously demonstrated the antiproliferative effects of Am80 in A549 cells (a human NSCLC cell line); however, we were unable to confirm whether Am80 induced the differentiation of pulmonary adenocarcinoma [14] .
In the present study, in order to evaluate the adaptability of Am80 as a differentiation inducer in pulmonary carcinoma, with the final goal of providing a new approach to pulmonary carcinoma therapy, we examined its effect on the viability and differentiation of a human NSCLC cell line, Calu-6. Calu-6 cells have been identified in anaplastic pulmonary carcinoma [15, 16] .
Materials and Methods

Ethics statement
All of the animal experiments were conducted with the approval of the Tokyo University of Science ethics committee (Approval Number Y15042). The administration of Am80 was stopped when the average tumor volume reached over 600 mm 3 or when necrosis was induced in the tumor. The animals were then euthanized and the tumors were enucleated at the next scheduled date of administration to ameliorate the pain and distress associated with tumor formation.
Materials
Am80, a gift from Itsuu Laboratory (Tokyo, Japan), was dissolved in ethanol and stored at -30°C until used in experiments. Goat anti-human CD90 (Thy-1) polyclonal antibody (#sc-6071) [17] , goat anti-human 
Cell lines
Calu-6 cells, an established human pulmonary carcinoma cell line (#HTB-56), was purchased from the American Type Culture Collection (Rockville, MD, USA).
Cell culture
Calu-6 cells were cultured with Eagle's minimal essential medium (EMEM; Wako Pure Chemical Industries, Ltd., Osaka, Japan) supplemented with 10% fetal bovine serum (FBS), non-essential amino acids, and 1 mM sodium pyruvate at 37°C in a humidified 5% CO 2 atmosphere.
Cell viability assay
The cellular viability of Calu-6 cells after Am80 treatment was assessed by a CellTiter-Glo Luminescent Cell Viability Assay (Promega KK, Tokyo, Japan), in compliance with the manufacturer's protocol. Cells were seeded (625 cells/cm 2 ) in 100 μL of medium in 96-well flat-bottom plates and incubated overnight at 37°C. After exposure to Am80 for 2-4 days, the plates were assayed with an EnVision Plate Reader (PerkinElmer Japan Co., Ltd., Kanagawa, Japan). The medium containing Am80 was replaced every 2 days.
Terminal deoxynucleotidyl
Transferase-mediated deoxyuridine triphosphate Nick End Labeling (TUNEL) staining
The cells were seeded (625 cells/cm 2 ) and incubated at 37°C. After exposure to Am80 for 4 days, the cells were fixed with 4% paraformaldehyde in phosphatebuffered saline (PBS). The cells were stained using an In situ Apoptosis Detection Kit, in compliance with the manufacturer's protocol (TaKaRa, Japan). The slides were washed with PBS three times and examined under a fluorescence microscope (Keyence, Japan). The apoptosis rate was determined by the number of TUNEL-positive cells/ 200 DAPI-positive cells.
The differentiation-inducing effect of Am80 in vitro
Calu-6 cells were seeded in 8-well plates at a density of 625 cells per cm 2 . After 24 h, cells were treated with various concentrations of Am80. Ethanol treated cells were considered as control cells. After 6 days of treatment, the cells were fixed in 4% paraformaldehyde in PBS and stained with primary antibodies CD90, SP-A, AQP-5, each at a dilution of 1:200 [17] [18] [19] . After mounting the sections, the nuclei were stained using DAPI and Donkey anti-goat IgG-FITC at a dilution of 
In vivo tumorigenesis assay
Five-week-old male congenital athymic BALB/C nude (nu/nu) mice were purchased from Sankyo Labo Service Corporation (Tokyo, Japan). A total of 6×10 5 Calu-6 cells were suspended in 100 µL of PBS (50% matrigel; Becton Dickinson & Co., San Jose, CA) and injected subcutaneously into both the left and right flanks of the nude mice. When the tumors exceeded 50 mm 3 in volume, the mice were divided randomly into control and Am80 groups (day 0). The twice weekly intratumoral administration of Am80 (0.2 mg/kg), dissolved in isotonic saline with DMSO at a concentration of 1%, was then initiated (day 0). The dose of Am80 was selected based on previous reports [21, 22] . The mice were weighed and the tumor volume was determined using the standard formula L×W 2 ×0.5, where L is the longest diameter and W is the shortest diameter, as previously described [23] .
Statistics
The normally distributed data are shown as the mean ± standard deviation (SD) or standard error (SE). Student's t-test was used for the comparisons of two groups. P-values of <0.01 or <0.05 were considered to indicate statistical significance
Results
In vitro cell-growth inhibition by Am80
Calu-6 cells were treated with different concentrations of Am80 for 2 and 4 days, and the cell viability determined by a CellTiter-Glo assay (Figure 1 ). Am80-treated cells exhibited reduced cell viability in a dose-and timedependent manner. The inhibition ratios of 10, 50, 100, and 200 μM Am80 for 4 days were approximately 5%, 61%, 64%, and 95%, respectively ( Figure 1A ). Am80 at a concentration greater than 100 μM reduced the viability of Calu-6 cells at 2 days of treatment ( Figure  1B) .
The induction of apoptosis in Calu-6 cells
The rate of TUNEL-positive cells in 200 DAPI-positive cells was 1.7 ± 1.6% in the control group and 1.6 ± 1.2% in the Am80 group. In this study, we could not confirm the induction of apoptosis by Am80 by TUNEL staining (Figure 2 ). This finding is consistent with a previous report which showed that Am80 may not induce apoptosis, or that growth inhibition may not be caused by apoptosis directly [14] .
The in vitro differentiation-inducing effect of Am80
We investigated whether Am80 had a differentiationinducing effect on Calu-6 cells, using specific markers (CD90 for anaplastic pulmonary cells, AQP-5 for type I alveolar epithelial cells, and SP-A for type II alveolar epithelial cells). CD90 is a specific marker of human alveolar epithelial progenitor cells [24] , and Calu-6 cells were positively stained for CD90. The culturing of Calu-6 cells with 100 μM Am80 for 6 days resulted in significant increases in the number of AQP-5-and SP-A-positive cells (Figure 3 ). Taken together, these findings reveal that Am80 induced the differentiation of Calu-6 cells to alveolar type I and II cells.
Am80-induced the growth inhibition of Calu-6 xenografts in vivo in nude mice
To evaluate the antitumor effect of Am80 on Calu-6 cells, we conducted an in vivo experiment using mice which harbor sc tumors composed of Calu-6 cells. The mean tumor volume was effectively inhibited after treatment with Am80 and the differences between the control and Am80 groups were significant from day 7 ( Figure 4A ). At the termination of the experiment, all of the mice were euthanized and the tumors were weighed. We also observed that the average weight of the tumors in the Am80 treated group was significantly reduced in comparison to that in the Control group ( Figure 4C) . We showed the antitumor effects of Am80 by the gross examination of the mice and tumors on day 31 ( Figures  4B and D) . The results showed that Am80 significantly influenced the suppression of tumor growth.
Discussion
We previously identified Am80 as an effective inhibitor of cell growth in a pulmonary adenocarcinoma cell line [14] . However, we could not conform the antiproliferative mechanism of Am80 in the previous study. We therefore investigated the effect of Am80 in Calu-6 cells, an anaplastic pulmonary carcinoma cell Next, as mentioned in our previous report, and in order to investigate the antiproliferative mechanism of Am80, we performed TUNEL staining to detect early cellular apoptosis. The result was that we were unable to confirm the induction of apoptosis by Am80 (Figure 2) . In a publication that elucidated the basic biological mechanisms of ATRA resistance in A549 human pulmonary carcinoma cells, ATRA was found to bind to RAR-α and promote phosphoinositide 3-kinase (PI3K)/Akt pathway activation, which is associated with cellular survival and invasion. It was found to suppress the transcription of genes associated with apoptosis, such as RAR-β2 and p53 by Akt activation [27] . Thus, Am80 may also inhibit growth without inducing apoptosis. Am80 has been shown to stimulate the differentiation of acute promyelocytic leukemia cells into neutrophils and induce neuronal differentiation in a human neuroblastoma NH-12 cell line [28, 29] . Based on the results of our investigation into whether Am80 had a differentiation-inducing effect on Calu-6 cells, we suggest that Am80 is a novel inducer of differentiation in anaplastic pulmonary carcinoma Calu-6 cells, which induces their differentiation into alveolar type I and II cells (Figure 3) . It is reported that Am80 induces differentiation via the PI3K/AKT and mitogenactivated protein kinase (MAPK) /extracellular signalregulated kinase (ERK) 1/2 pathways in the NB-4 acute myelocytic leukemia cell line [30] ; thus, differentiation may be induced via a similar pathway in anaplastic pulmonary carcinoma. On the other hand, it is reported that the induction of RAR-β expression is significant for the inhibition of tumor cell growth [31] . Furthermore, Am80 also induced differentiation in alveolar epithelial type II progenitor cells and inhibited the expression of Wnt1 and induced neurexin3 (NRXN3), which contribute to differentiation [32, 33] . Thus, to elucidate the relationship between those molecular mechanisms and Am80 activity, it is important to understand the antiproliferative and differentiation-inducing effect of Am80.
Am80 inhibits rat collagen arthritis and ameliorates experimental autoimmune myositis [34, 35] . The antitumor activity of Am80 against human leukemic monocyte lymphoma cell U937 tumor xenografts has also been demonstrated in vivo [36] . That said, there are no reports to indicate that Am80 is effective against the growth of pulmonary carcinoma cells. In the present study, in order to investigate whether Am80 inhibits tumor growth in vivo, we conducted experiments in mice harboring sc tumors composed of Calu-6 cells. The mice were treated with Am80 (0.2 mg/kg) and the tumor volume measured twice per week. The results revealed that Am80 treatment reduced the tumor volume and weight (Figure 4) . We revealed the antitumor effects of Am80 on Calu-6 tumors; however, the relationship between the mechanism of tumor volume reduction and the differentiation effect in vitro were not clearly elucidated. Thus, in the future, further study will be needed to investigate the contribution of the differentiation effect of Am80 to the inhibition of tumor growth, including the molecular mechanisms.
Conclusions
Am80 had a significant influence on the suppression of tumor growth. We revealed that Am80 induced the differentiation of Calu-6 cells and that it can be used as an effective cell-growth inhibitor and differentiation inducer in pulmonary adenocarcinoma. Evidence that retinoic acid receptor beta induction
